Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Return on Equity: 2022-2025

Historic Return on Equity for Taysha Gene Therapies (TSHA) over the last 3 years, with Sep 2025 value amounting to -0.40%.

  • Taysha Gene Therapies' Return on Equity rose 42.00% to -0.40% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.40%, marking a year-over-year increase of 42.00%. This contributed to the annual value of -1.16% for FY2024, which is 79.00% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported Return on Equity of -0.40% as of Q3 2025, which was up 29.79% from -0.57% recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Return on Equity registered a high of 19.04% during Q1 2023, and its lowest value of -28.49% during Q4 2022.
  • Over the past 3 years, Taysha Gene Therapies' median Return on Equity value was -0.82% (recorded in 2024), while the average stood at 1.31%.
  • In the last 5 years, Taysha Gene Therapies' Return on Equity skyrocketed by 2,277bps in 2023 and then plummeted by 2,027bps in 2024.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Return on Equity stood at -28.49% in 2022, then surged by 2,277bps to -5.72% in 2023, then skyrocketed by 467bps to -1.06% in 2024, then spiked by 42bps to -0.40% in 2025.
  • Its Return on Equity was -0.40% in Q3 2025, compared to -0.57% in Q2 2025 and -1.30% in Q1 2025.